Ingevity posts $146.5 million Q2 loss on $183.8 million impairment; raises EBITDA floor
Ingevity reported second quarter 2025 net sales of $365.1 million, down 7%, and a net loss of $146.5 million, or $4.02 per diluted share, which included a $183.8 million non-cash goodwill impairment tied to the Advanced Polymer Technologies segment. Adjusted earnings rose 39% to $51.1 million, and the company raised the low end of its full-year adjusted EBITDA guidance to a range of $390 million to $415 million while maintaining its sales guidance of $1.25 billion to $1.40 billion.
Key points
- Q2 net sales were $365.1 million, down 7%, mainly due to lower Performance Chemicals sales
- Net loss of $146.5 million and diluted loss of $4.02 per share, including a $183.8 million goodwill impairment
- Adjusted earnings rose 39% to $51.1 million; diluted adjusted EPS was $1.39, up 38%
- Full-year 2025 adjusted EBITDA guidance is $390 million to $415 million; sales guidance remains $1.25 billion to $1.40 billion
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.